Zc(=o)oy, Wherein Z Is An Acyclic Radical Bonded To The C=o By A Carbon And Y Is An Organic Radical Bonded To The Oxygen By A Carbon Patents (Class 514/546)
Abstract: Methods of retarding formation of a lipofuscin pigment in the retina and of treating or ameliorating the effects of a disease characterized by an accumulation of a lipofuscin pigment in a retina are provided. These methods include the step of administering to a patient in need thereof a substituted C20-retinoid in an amount sufficient to reduce accumulation of a lipofuscin pigment in the retina. Further provided are methods of retarding formation of A2E and/or ATR-dimer by replacing an all-frans-retinal (ATR) substrate with a C20-D3-retinal substrate under conditions sufficient to impede the formation of A2E. Compositions for retarding formation of a lipofuscin pigment in the retina containing a substituted C20-retinoid and a pharmaceutically acceptable carrier are also provided.
Type:
Grant
Filed:
September 12, 2008
Date of Patent:
November 4, 2014
Assignee:
The Trustees of Columbia University in the City of New York
Abstract: An antimicrobial composition and method for extending the shelf-life of water, food/feed or food/feed ingredients, comprising: 5-25 wt. % nonanoic acid, 1-25 wt. % organic acid ester, 1-50 wt. % of a single or mixture of C1-C24 aldehydes, a mixture of C1-C24 organic acids, and water.
Abstract: Hydrophobic liquids are microencapsulated by an enteric matrix in an environment substantially free of organic solvents. The process includes forming an emulsion of the enteric material and hydrophobic liquid in water, titrating the emulsion with an acid to form a particulate precipitate and optionally coating the particulate with a combination of enteric material and plasticizer.
Type:
Grant
Filed:
December 22, 2010
Date of Patent:
October 14, 2014
Assignee:
Intercontinental Great Brands LLC
Inventors:
Ahmad Akashe, Anilkumar Ganapati Gaonkar, Les Lawrence, Amado R. Lopez, George W. Haas, Dana Sebesta, Yan Wang
Abstract: The present invention provides a method for stimulating hair growth in a mammalian species or converting vellus hair or intermediate hair to terminal hair or stimulating hair follicles to increase hair growth and one or more properties selected from the group consisting of luster, sheen, brilliance, gloss, glow, shine or patina of hair associated with the follicles or increasing one or more of: length, thickness, number, and density, of eyelash hair or eyebrow hair comprising applying to the skin of a patient a composition comprising an effective amount of an EP3 agonist or an EP4 agonist prodrug or a mixture thereof. Such compositions which are used in treating the skin or scalp of a human or non-human animal may comprise an effective amount of 3, 7 or 3 and 7 thia prostanoic acid. A mixture of 3,7-dithia PGE1 and 3,7-dithia PGE1-isopropyl ester is preferred for this treatment.
Abstract: The present invention provides a series of derivatives of stilbenoid which are useful as new inhibitory agents against head and neck squamous cell carcinoma (HNSCC) and hepatoma.
Abstract: Anhydrous agents for topical application, comprising one or more C1-C4 alkyl esters of lactic acid, malic acid, tartaric acid or citric acid and physiologically acceptable excipients, are described for the treatment of nail disorders caused by mycoses and for nail care. The agents according to the invention are also suitable in veterinary medicine for treating fungal infections of the hooves, claws and talons of pets and farm animals and wild animals living in captivity.
Abstract: A novel amine compound represented by the following formula (I), which is superior in immunosuppressive action, rejection suppressive action and the like, and shows reduced side effects such as bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or hydrates thereof, or solvate, as well as a pharmaceutical composition containing this compound and a pharmaceutically acceptable carrier. wherein R is a hydrogen atom or P(?O)(OH)2, X is an oxygen atom or a sulfur atom, Y is CH2CH2 or CH?CH, R1 is cyano or alkyl having a carbon number of 1 to 4 and substituted by a halogen atom(s), R2 is alkyl having a carbon number of 1 to 4 and optionally substituted by a hydroxyl group(s) or a halogen atom(s), R3 and R4 may be the same or different and each is a hydrogen atom or alkyl having a carbon number of 1 to 4, and n is 5-8.
Abstract: A method is provided for treating a subject in need of therapy for depression, anxiety, impaired cognition and/or pain comprising administering to said subject an amount of a ketogenic material sufficient to produce a ketosis in the subject sufficient to provide anti-depressant effect, cognition enhancing and/or analgesic effect. Preferred materials produce a ketosis is such that the total concentration of acetoacetate and (R)-3-hydroxybutyrate in the blood of the subject is raised to between 0.1 and 30 mM.
Abstract: The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain disorder (CRPS) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.
Type:
Application
Filed:
October 15, 2012
Publication date:
October 2, 2014
Inventors:
Irving W. Wainer, Ruin Moaddel, Michel Bernier, Carlos A. Zarate, Marc C. Torjman, Michael E. Goldberg, Mary J. Tanga
Abstract: A method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases.
Abstract: An edible oil obtained by culturing a microorganism belong to the genus Mortierella subgenus Mortierella in a medium containing a nitrogen source derived from soybean is discussed. The oils obtained have a low 24,25-methylenecholest-5-en-3?-ol content.
Abstract: Pro-drugs of 1-(2-halo-biphenyl-4-yl)alkanecarboxylic acids are useful for preventing and/or treating neurodegenerative diseases, improving cognitive function and treating cognitive impairment.
Abstract: A stable aqueous solution of sodium pyruvate for medical use, which contains 10-1,200 mM sodium pyruvate and a stabilizer of sodium pyruvate, wherein the said stabilizer is H+ which leads to pH 3.0-6.0 or NaCl which provides at least 20 mM Na+.
Abstract: This invention relates to the field of therapeutic agents for the treatment of Age-Associated Memory Impairment (AAMI). In particular, the present invention utilizes compositions comprising at least one compound capable of elevating ketone body concentrations in a mammal (e.g., ketogenic compounds), administered in an amount effective for treatment or prevention of loss of cognitive function caused by reduced neuronal metabolism in AAMI. In one embodiment, the composition includes medium chain triglycerides (MCT). In another embodiment, the compositions are administered in the presence of carbohydrate. The present invention also relates to oral dosage forms, in particular, a nutritional drink comprising at least one compound capable of elevating ketone body concentrations in a mammal.
Abstract: The present invention relates to a granulate and a pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof and stabilizer, in particular to a pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof and sucrose, polyethylene glycol, cyclodextrin, and combinations thereof and to a process for its preparation. The granulate and the pharmaceutical composition are particularly useful as a medicament, especially for the treatment of urinary incontinence. The present invention relates to use of sucrose, polyethylene glycol, cyclodextrin, and combinations thereof for stabilizing fesoterodine or a salt or a solvate thereof in a pharmaceutical composition.
Type:
Application
Filed:
April 10, 2012
Publication date:
September 4, 2014
Applicant:
LEK PHARMACEUTICALS D.D.
Inventors:
Sara Cesar, Klemen Naversnik, Tijana Stanic-Ljubin
Abstract: Provided herein are methods of preventing a fibrotic response and/or scarring in a wound, comprising administering to a subject a composition comprising an amount of an amide or ester of an alpha-ketoalkanoic acid effective to inhibit a proliferative and/or fibrotic response in the wound. In one instance, the wound is to a subject's cornea, such as a wound resulting from refractive surgery. In one embodiment, the amide or ester of an alpha-ketoalkanoic acid is ethyl pyruvate.
Type:
Grant
Filed:
January 26, 2009
Date of Patent:
August 26, 2014
Assignee:
University of Pittsburgh—of the Commonwealth System of Higher Education
Inventors:
Weixang Dai, James L. Funderburgh, Joel S. Schuman, Nirmala SundarRaj
Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, dermatitis.
Type:
Grant
Filed:
August 15, 2011
Date of Patent:
August 26, 2014
Assignee:
AmDerma Pharmaceuticals, LLC
Inventors:
Pedro Cueva Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
Abstract: Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.
Type:
Application
Filed:
April 17, 2014
Publication date:
August 21, 2014
Applicants:
The Hospital for Sick Children, McMaster University
Inventors:
Don J. Mahuran, Michael B. Tropak, Justin D. Buttner, Jan E. Blanchard, Eric D. Brown
Abstract: Disclosed is a pharmaceutical composition for the prevention or treatment of ischemic heart diseases, comprising as an active ingredient an inhibitor which acts to restrain mononuclear phagocyte system cells from synthesizing or releasing AGE-albumin, which induces the apoptosis of cardiomyocytes upon the onset of the ischemic heart disease. Also, a method is provided for screening an inhibitor against the AGE-albumin synthesis or release of mononuclear phagocyte system cells. Inhibitory or suppressive of AGE-albumin-induced cell death, the pharmaceutical composition comprising as an active ingredient an inhibitor against the AGE-albumin synthesis or release of mononuclear phagocyte system cells can be applied to the prevention or treatment of a wide spectrum of ischemic heart diseases including myocardial infarction.
Abstract: The compound of formula (I): is provided. It may be produced by subjecting a compound of formula (IV) to a reduction reaction wherein R represents hydrogen, straight or branched C1-C6 alkyl. This compound is a valuable intermediate which may be used in the synthesis of fesoterodine, tolterodine, its active metabolite, and related compounds.
Abstract: The topical ophthalmic use of 5,6,7-trihydroxyheptanoic acid and analogs for the acceleration of corneal wound healing in humans, is disclosed.
Type:
Application
Filed:
January 16, 2014
Publication date:
August 14, 2014
Applicant:
Alcon Research, Ltd.
Inventors:
Daniel A. Gamache, Mark R. Hellberg, Peter G. Klimko, Kerry L. Markwardt, John M. Yanni, Eric C. Carlson
Abstract: Biodegradable detergent compositions comprising enzymes and 1,3-propanediol are provided. The 1,3-propanediol in the composition is biologically derived and enhances the stability of the enzymes in the composition. The compositions also exhibit a low anthropogenic CO2 emission profile.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
August 12, 2014
Assignee:
DuPont Tate & Lyle Bio Products Company, LLC
Inventors:
Gyorgyi Fenyvesi, Melissa Joerger, Robert Miller, Raja Hari Poladi, Ann Wehner
Abstract: This invention is based upon the discovery that a mixture of ethyl lactate and isoamyl lactate can be used to improve the penetration of active ingredients in skin care formulations through the outer layers of the stratum corneum and viable epidermis and into the dermis layer of the skin structure. The present invention more specifically discloses a method of rejuvenating skin affected by intrinsic aging and/or photo-induced aging comprising topically applying a topical formulation to the skin, wherein said topical formulation is comprised of ascorbic acid, an amino acid selected from the group consisting of phenylalanine and tyrosine, a non-toxic zinc salt, carnosic acid, ?-tocopherol, 0.01 weight percent to 20 weight percent of a mixture of ethyl lactate and isoamyl lactate, wherein the weight ratio of the ethyl lactate to the isoamyl lactate is within the range of 1:10 to 20:1, and a pharmaceutically acceptable carrier.
Abstract: Compositions useful for controlling pests are disclosed. In some embodiments, the composition includes a pesticidal natural oil and a polar aromatic solvent or an alkyl alcohol solvent. Methods of making and using the compositions are disclosed.
Abstract: The invention features methods of inhibiting the growth of, or killing, fungal and certain bacterial microorganisms with one or more of a family of glycerol-based compounds.
Type:
Grant
Filed:
August 2, 2005
Date of Patent:
August 5, 2014
Assignee:
Regents of the University of Minnesota
Inventors:
Patrick M. Schlievert, Marnie L. Peterson
Abstract: The present invention provides a compound of formula (I) or a prodrug thereof useful for treating or preventing irritable bowel syndrome, and a composition comprising the compound as an active ingredient. Also, the present invention provides a method for treating or preventing irritable bowel syndrome, which comprises administrating a therapeutically or prophylactically effective amount of the compound or the composition to a subject in need of treating or preventing irritable bowel syndrome.
Type:
Application
Filed:
May 16, 2012
Publication date:
July 31, 2014
Applicant:
SK CHEMICALS CO., LTD.
Inventors:
Won suk Sun, Hyo Jin Jeon, Dongsun Min, Woongsik Kim, Taeksu Kim, Do-Seung Kum, Keun-Ho Ryu, Hae-In Rhee, Yang Hae Park, Hyun-Joo Son, Eun-ju Park, Bong-yong Lee, Hojin Namgung, Minseok Park, Minseok Kang
Abstract: This invention relates to pharmaceutical compounds and nutritional supplements that are acetylated derivatives of naturally occurring amino acids and acetylated derivatives of peptides derived from naturally occurring amino acids containing hydroxyl groups. They are as useful as anti-platelet drugs, and as nutritional supplements.
Abstract: A compound which is 3-hydroxybutyl 3-hydroxybutyrate enantiomerically enriched with respect to (3R)-hydroxybutyl (3R)-hydroxybutyrate of formula (I) is an effective and palatable precursor to the ketone body (3R)-hydroxybutyrate and may therefore be used to treat a condition which is caused by, exacerbated by or associated with elevated plasma levels of free fatty acids in a human or animal subject, for instance a condition where weight loss or weight gain is implicated, or to promote alertness or improve cognitive function, or to treat, prevent or reduce the effects of neurodegeneration, free radical toxicity, hypoxic conditions or hyperglycaemia.
Type:
Application
Filed:
December 10, 2013
Publication date:
July 10, 2014
Applicants:
Government of the USA, as Represented by the Secretary, Department of Health and Human Services, Isis Innovation Limited
Abstract: A process for the preparation of (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)-phenol isobutyrate (Fesoterodine) or a pharmaceutically acceptable salt thereof having low content in impurities.
Type:
Grant
Filed:
November 14, 2011
Date of Patent:
July 8, 2014
Assignee:
Dipharma Francis S.r.l.
Inventors:
Marco Artico, Emanuele Attolino, Pietro Allegrini, Gabriele Razzetti
Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
Type:
Application
Filed:
December 23, 2013
Publication date:
July 3, 2014
Applicant:
AERIE PHARMACEUTICALS, INC.
Inventors:
Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
Abstract: Disclosed is a pharmaceutical composition comprising a pyrazine derivative represented by the general formula: [wherein R1 and R2 independently represent a hydrogen atom or a halogen atom; and R3 represents a hydrogen atom or an amino-protecting group] or a salt thereof and at least one neuraminidase inhibitor. The pharmaceutical composition is useful for a treatment including the treatment or prevention of influenza. Also disclosed is a method of using these components in combination. The method is useful for a treatment including the treatment or prevention of influenza.
Abstract: A coenzyme Q10-containing composition comprising a coenzyme Q10 and a hydrophilic fatty acid ester of a polyhydric alcohol; a coenzyme Q10-containing composition comprising a coenzyme Q10, a lipophilic fatty acid ester of a polyhydric alcohol and a hydrophilic fatty acid ester of a polyhydric alcohol; and a food or beverage comprising the coenzyme Q10-containing composition as defined above.
Abstract: Disclosed is the use of a mist of a pharmaceutical composition for ophthalmic delivery of a protein or peptide active pharmaceutical ingredient, a related method of treatment and a device useful in implementing the use and method. Disclosed is also the use of a mist for ophthalmic delivery of a pharmaceutical composition including a highly irritating penetration enhancer and an ophthalmically acceptable carrier, a related method of treatment and a device useful in implementing the use and method. Disclosed is also a device for ophthalmic administration configured to direct a mist of a pharmaceutical composition to the eye only when the eye is open. Disclosed is also a self-sterlizing device for ophthalmic administration. Disclosed is also a device and a method for increasing the bioavailability of an ophthalmically administered API in a pharmaceutical composition.
Type:
Application
Filed:
August 9, 2013
Publication date:
June 19, 2014
Applicant:
PHARMALINGT INC.
Inventors:
Yossi Gross, Rafi Herzog, Steven B. Koevary
Abstract: The objective of the present invention is to provide an antimicrobial composition that can be safely used with a broad range of foods and beverages, cosmetics, drugs, and other similar products while showing growth inhibition activity against a wide variety of microorganisms. The present invention relates to the antimicrobial composition comprising at least one cooling agent selected from the group consisting of menthyl 3-hydroxybutanoate, 2-methyl-3-(menthoxy)propane-1,2-diol, 2-(menthoxy)ethanol, 3-menthoxypropan-1-ol, 2-(2-menthoxyethoxy)ethanol, and menthyl glyoxylate.
Type:
Application
Filed:
February 12, 2014
Publication date:
June 12, 2014
Applicant:
TAKASAGO INTERNATIONAL CORPORATION
Inventors:
Kenya ISHIDA, Tomoko YAMAMOTO, Miho SUZUKI
Abstract: Provided is a method of relieving, improving, preventing or treating xerostomia including applying an oral cavity composition including a polyethylene glycol (PEG) derivative whose reactor is modified to form a covalent bond with an epithelial cell of the oral cavity. An oral moisturizing effect and moisture persistency are increased and the method is effective against xerostomia due to aging or disease.
Type:
Application
Filed:
October 4, 2013
Publication date:
June 5, 2014
Inventors:
KWANG NHO, Min Jung AHN, Byung Hee SOHN, Chang Min HYUN, Jung Hun LEE
Abstract: The invention relates to the use of long chain polyunsaturated fatty acids for the manufacture of a nutritional composition for feeding infants of a mother who suffered from a metabolic disorder during pregnancy and to a corresponding composition. Said composition comprises a n-3 polyunsaturated fatty acid fraction containing at least 0.1 wt % docosahexaenoic acid (DHA) based on total weight of the lipid, at least 0.01 wt % n-3 docosapentaenoic acid (DPAn-3) based on total weight of the lipid, and at least 0.01 wt. % eicosapentaenoic acid (EPA) based on total weight of the lipid, wherein the sum of DHA, DPAn-3 and EPA is below 1 wt. % of total lipid.
Type:
Grant
Filed:
October 3, 2011
Date of Patent:
May 20, 2014
Assignee:
N.V. Nutricia
Inventors:
Bernd Stahl, Gunther Boehm, Christopher Beermann, Johan Garssen
Abstract: Suggested are biocide compositions, comprising (a) esters based on ketocarboxylic acids, (b) biocides, and optionally (c) oil components or co-solvents and/or (d) emulsifiers. The compositions exhibit an improved stability even if stored at temperatures between 5° and 40° C. over a longer period.
Type:
Grant
Filed:
August 24, 2010
Date of Patent:
May 20, 2014
Assignee:
Cognis IP Management GmbH
Inventors:
Joaquin Bigorra Llosas, Stéphanie Merlet, Ramon Valls, Stefan Busch
Abstract: The present invention relates to formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid in Form I, pharmaceutical packs or kits thereof, and methods of treatment therewith.
Abstract: Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis, which is the % of glucose production that comes from gluconeogenesis (“GNG”), as opposed to glycogenolysis (“GLY”), the other form of glucose production. Nutritional formulations, materials, cocktails and methods for feeding patients by parenteral and other means are disclosed. The amount, type and rate of such nutritional feeding are typically based upon the above estimating. The invention discloses formulations that contain labels, such as deuterium, for medical diagnostics, such as for estimating BES and fractional gluconeogenesis.
Abstract: The invention provides compounds of Formula (I): R1?R2??(I) wherein R1 and R2 have any of the values or specific values defined herein, as well as compositions comprising such compounds and therapeutic methods comprising the administration of such compounds.
Type:
Grant
Filed:
May 23, 2012
Date of Patent:
April 22, 2014
Assignee:
University of Louisville Research Foundation, Inc.
Inventors:
Gerald B. Hammond, Bo Xu, Paula J. Bates
Abstract: Derivatives of plumbagin can be selectively cytotoxic to breast cancer cells. Derivative ‘A’ (Acetyl Plumbagin) has emerged as a lead molecule for testing against estrogen positive breast cancer and has shown low hepatotoxicity as well as overall lower toxicity in nude mice model. The toxicity of derivative ‘A’ was determined to be even lower than vehicle control (ALT and AST markers). The possible mechanism of action identified based on the microarray experiments and pathway mapping shows that derivative ‘A’ could be acting by altering the cholesterol-related mechanisms. The low toxicity profile of derivative ‘A’ highlights its possible role'as future anti-cancer drug and/or as an adjuvant drug to reduce the toxicity of highly toxic chemotherapeutic'drugs.
Type:
Application
Filed:
March 13, 2013
Publication date:
April 17, 2014
Applicant:
KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
Inventor:
KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
Abstract: The present invention relates to a process for the preparation of an ester comprising an after-treatment of the ester to give an ester in granule form of defined particle size distribution, a device for carrying out this process, a process for the preparation of a thermoplastic composition comprising the ester prepared according to the invention, a process for the production of a shaped article comprising the ester according to the invention or the thermoplastic composition according to the invention, a process for the production of a packed product, a process for the production of an at least partly coated object, and uses of the esters according to the invention as an additive in various compositions.
Type:
Application
Filed:
February 21, 2012
Publication date:
April 17, 2014
Inventors:
Peter Daute, Wilhelm Reiners, Martin Schäfer, Udo Frerichs, Hinrich Hildebrandt, Joern Ellerbrake
Abstract: Compositions and methods for controlling and/or repelling bedbugs are provided. The compositions comprise one or more compounds having bedbug repellant activity. Such compounds may be, for example, naturally occurring semiochemicals or structural or functional analogs of naturally occurring semiochemicals. Exemplary compounds are compounds of general formula (I).
Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease. The phorbol esters described are particularly useful in the treatment of neoplastic diseases and/or managing the side effects of chemotherapeutic and radiotherapeutic treatments of neoplastic diseases.
Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.
Type:
Application
Filed:
October 7, 2005
Publication date:
April 10, 2014
Applicant:
Forward Pharma A/S
Inventors:
Henrik NILSSON, Florian SCHOENHARTING, Bernd W. MUELLER, Joseph R. ROBINSON
Abstract: Disclosed herein is an isolated Muscodor albus strain producing volatile organic compounds such as aristolene, 3-octanone and/or acetic acid ester, as well as cultures of said strain and compositions, metabolites and volatiles derived from said strain or culture as well as methods of obtaining said compositions, metabolites and volatiles and their methods of use for controlling pests. Also disclosed are artificial compositions having the same components and uses as the volatiles derived from the strain. A method for capturing and sampling the volatiles is also disclosed.
Type:
Application
Filed:
March 15, 2013
Publication date:
March 27, 2014
Applicant:
MARRONE BIO INNOVATIONS, INC
Inventors:
Gary Strobel, Vu Phong Bui, Hai Su, Phyllis Himmel, Pamela Marrone, Lijuan Xing
Abstract: Disclosed herein is an isolated Muscodor albus strain producing volatile organic compounds such as aristolene, 3-octanone and/or acetic acid ester, as well as cultures of said strain and compositions, metabolites and volatiles derived from said strain or culture as well as methods of obtaining said compositions, metabolites and volatiles and their methods of use for controlling pests. Also disclosed are artificial compositions having the same components and uses as the volatiles derived from the strain. A method for capturing and sampling the volatiles is also disclosed.
Type:
Application
Filed:
September 23, 2013
Publication date:
March 27, 2014
Applicant:
Marrone Bio Innovations, Inc.
Inventors:
Gary Strobel, Vu Phong Bui, Hai Su, Phyllis Himmel, Pamela Marrone, Lijuan Xing, Sarah Lewis